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Abstrat
Today massively parallel DNA sequening platforms are beome widely
available, reduing the osts and the time of DNA sequening.
Next Generation Sequeners (NGSs) allow to obtain large amount of data
and they open new perspetives in elds like genomi and medial researh.
One of the most promising appliation in medial researh and in diagnosti
is the exome sequening,a spei targeted re-sequening of the known exons.
There are two advantage in sequening the exome:
• The human exome is the 1% of the total genome (about 30Mbp) and
it is so possible to obtain high overage with low osts.
• Several variations in exome ause diseases.
These two features make the exome sequening very interesting and inreas-
ingly used by sientists. There are several strategies for exome sequening
but, we onsidered Illumina and SOLiD approahes.
In details, we analyzed 6 patients aeted by arrhythomogeni ardiomy-
opathy. Geneti variations in these patients were already haraterized with
Sanger tehnologies so we ould ompare dierent variant detetions algo-
rithm with SOLiD reads and with Illumina reads.
Results onrmed the key role of overage in deteting variants.
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Abstrat - ITALIANO
Attualmente le tenologie di sequenziamento massivo del DNA sono di-
ventate ampiamente disponibili e hanno ridotto sia i osti he i tempi di
sequenziamento.
I sequenziatori di nuova generazione (NGS) permettono di ottenere grosse
moli di dati e hanno aperto nuove prospettive nel ampo della genomia e
della riera media.
Tra le appliazioni più promettenti nel ampo della riera media e della
diagnostia spia il sequenziamento dell'esoma denibile ome uno speio
targeted resequening degli esoni noti. Ci sono due vantaggi nel sequenziare
l'esoma:
• L'esoma umano è ira l'1% del totale del genoma (ira 30 Mbp) per
ui è possibile ottenere alte operture on osti ridotti.
• Mutazioni a livello esonio sono alla base di molte patologie.
Queste aratteristihe rendono il sequenziamento dell'esoma molto interes-
sante e sempre più utilizzato dagli studiosi. Esistono molte strategie per il
sequenziamento dell'esoma, ma in questa tesi verranno onsiderati gli approi
tramite Illumina e SOLiD. Nel dettaglio verranno analizzati 6 pazienti af-
fetti da ardiomiopatia aritmogenia. Le varianti generihe in questi pazienti
sono già state aratterizzate on tenologia Sanger e si vogliono omparare
diversi algoritmi di riera delle varianti on le sequenze Illumina e SOLiD.
I risultati onfermano l'importanza del overage di sequenza.
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Introdution
In this PHD thesis, I take into onsideration a spei appliation of Next
Generation Sequeners (NGSs): the human exome resequening. Sequening
an exome (speially the human exome) was unthinkable few years ago but,
today it is only one of the appliations of NGSs.
Untill NGS, in the genomi eld the problems were to obtain suient data
reduing the osts and time: sequening an eukaryoti genome ould take
several years and lot of sientist eorts. Currently, the same goal an be
obtained in few weeks with a biologist, a bioinformatis, and a Next Gener-
ation Sequener.
In this senario, it ould seem that NGSs solve the major part of problems of
the -omis sienes. But this is not true. NGSs solved the problem of "how
to obtain the data" but they do not solve the problem of "how to manage
and analyse the data".
NGSs hanged the role of bioinformati that is beame a fundamental g-
ure in every laboratory whih has or have had data from NGSs. The ma-
jor problems today are omputational power, informatis spae and apable
bioinformatis.
In this thesis the rst 2 hapters are general onsideration about NGSs and
their prinipal appliations. Chapters 3 is a deepening in exome resequen-
ing. Chapter 4 and 5 are bioinformatial deeping in aligning and SNP alling.
Chapter 6 is the appliation of exome resequening on the arrhythomogeni
ardiomyopathy both for diagnosti and researh. I onsidered 6 patients,
already haraterized with Sanger tehnology, and I investigated about the
dierent algorithms.
The aim of this PHD thesis is to understand the limits and the apability of
exome sequening to identify SNPs and INDELs. I analyzed dierent sam-
ples with dierent overages and in one ase with dierent tehnologies. In
this senario, I ould understand when a variant an be onsidered reliable
or not, that is very important for using the exome sequening in diagnosti
and in researh elds.
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1.1 Introdution
With Next Generation Sequening (NGS), we onsider all sequene teh-
nologies where:
• Baterial loning phase is by-passed.
• Sequening is performed at the same time over all DNA fragments
These two improvements allowed to redue time and osts of sequening and
an inreasingly number of laboratories has today aess to sequening teh-
nologies.
The bottle-nek is still the data analyses[14℄ baause the large amount of
data produed by NGS is diult to manage and analyze.
1.2 Rohe 454 sequener
454 was the rst next generation system ommerialized by Rohe. This
sequener is based on pyrosequening tehnology[1℄ that depends on the de-
tetion of pyrophosphate released during nuleotide inorporation.
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Figure 1.1: 454 Pyrosequening workow[44℄
The DNA is fragmented with physial methods and speial adaptors were
ligated to the end. The DNA is aptured by beads and then it is amplied
with an emulsion PCR. Beads are then deposited on a piotiter plate (PTP)
with all neessary sequening enzymes.
Sequener let ow one of dNTP in a ontrolled series and the pyrophosphate,
released by an inorporation, beome substrate of sulfurylase, luiferase and
luiferin and there is emission of light[33℄.
The order of nuleotides allow to know the sequene of the reads, and the
light intensity the number of inorporated nuleotides.
The read length of Rohe 454 is now around 600/800 bases and the through-
put is around 1 Gbp[2℄ but, 454 throughput is less than the SOLiD or IL-
LUMINA one, so 454 is not used for exome resequening. Costs should be
too high.
The most outstanding advantage of Rohe is its speed and the reads length.
One run takes 24 hours and the reads have a length similar to Sanger teh-
nology ones.
1.3 Illumina HiSeq sequener
Illumina sequeners are based on sequening by synthesis (very similar to
Sanger tehnology). The DNA is broken is small fragment (around 400/600
bases), ligated to spei adaptors and, then plaed in a partiular owell
with xed primers. On the owell the DNA is amplied by bridge ampli-
ation to reate lusters of lonal moleules.
Sequening is performed by synthesis adding nuleotides ontaining uores-
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Figure 1.2: Illumina workow[44℄
ent dye; the signal is aptured by a CCD amera.
There are several versions of Illumina sequener, for example HiSeq 1000 pro-
dues 300 Gbp per run in 8 days[3℄. The reads are from 50 to 150 nuleotides
depending on sequener version and sequening kit used.
1.4 Applied Biosystem SOLiD sequener
SOLiD is aronym of Sequening by Oligo Ligation Detetion and its
sequening method is based on ligation. The sequener adopts the tehnology
of two-base sequening based on ligation sequening.
DNA is amplied by emulsion PCR (similar to 454) and then it is plaed
on owell. Sequening is performed by adding 8 base-probe ligation whih
ontains ligation site (the rst base), leavage site (the fth base), and 4
dierent uoresent dyes (linked to the last base)[44℄. Every uoresent
dyes represents 2 bases.
Whit SOLiD tehnology every base is sequened two times and the output
is in olor spae format. Color spae is dierent from base spae (Illumina,
454 and Sanger output) and it needs of dediated software.
SOLiD throughput is similar to Illumina one and reads length varies from
35 to 75 base pairs.
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Figure 1.3: SOLiD workow[44℄
1.5 Other Sequeners
Beyond the three sequeners 454, Illumina and SOLiD, there are other
next generation sequeners that start to be establish in the NGS market.
Among them, Ion Proton and Ion Torrent (both of Applied Biosystem) are
the most known. Both sequeners use a sequening strategy similar to 454,
but they do not measure the light intensity of pyrophosphate but the H
+
variation.
1.6 NGS impat on geneti researh
New sequeners allowed to obtain large amount of data in very few time.
Costs are also redued (see gure 1.4), so, muh more sientists than in the
past, have today aess to genomi or transriptomi data. The problem
today is not obtain the data but it is the manegment of these data and their
proessing. One run of SOLiD or ILLUMINA an produe up to 300 Gbp
and their proessing an double or triple the data.
To manage this data it is neessary to have lusters of hard disk and, anal-
ysis an be performed only if it is available big omputers, or lusters, with
a large number of CPU and lot of RAM.
These problems are often underestimated and sientists have diult to an-
alyze their data for their researhes.
All these troubles an be solved buying hardware or using louds system suh
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Sequener Read
length
throughput Sequening
method
Output
Format
454 up to 800
bp
up to 1Gbp Pyrosequening s format
Illumina from 50 to
150 bp
up to 300
Gbp
Sequening by
sinthesis
fastq for-
mat
SOLiD from 35 to
75
up to 200
Gbp
Sequening by
ligation
olor spae
format
Table 1.1: Table of prinipal NGSs and their output
Figure 1.4: Costs of sequening per base against time
as Amazon (http://aws.amazon.om/e2/) but this is only a partial solution
beause these data have to be sent to the remote omputer and net transfers
an be a real bottle-nek: transferring an Illumina run an take up to 10 or
20 days.
At the same time, having hardware is not always the solution. In fat, bioin-
formati apabilities are obligatory to perform the analysis.
In this senario, the bioinformati beame a gure very important in every
laboratories whih manage NGS experiments.
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2.1 Introdution
NGSs opened new perspetive in genomi researh. Often the unique
limit is the osts. Currently NGSs are used for:
• DeNovo Sequening
• Resequening
• RNA-seq and DeNovo transriptomi sequening
• Metagenomis
Theorially all the NGSs ould be used for these appliations but, often
the hoise is taken onsidering: osts, bioinformati analysis, read lengths
and read quality.
2.2 DeNovo Sequening
The term "DeNovo Sequening" is often onfuse with "DeNovo sequene
assembly". Even if these two terms seem synonyms, they are very dierent.
NGSs allow today to perform the "DeNovo Sequening" with low osts (than
the past) and with redued time, but the "DeNovo sequene assembly" re-
mains a hallenging tasks. DeNovo Sequening is the proess with whih we
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obtain a series of read that potentially over all the genome of an organism.
Generally a DeNovo sequening is measured by overage:
AV G_Coverage =
(
Sequenced_bases
Genome_Size
)
Where AVG_Coverage is the average overage, Sequened_bases are the
number of bases obtained by sequening and Genome_Size is the size of se-
quened genome in bases.
"De Novo Sequening assembly" is the proess whereby we merge together
individual sequene reads to form long ontiguos sequenes (ontig) sharing
the same nuleotide sequene reads were derived[43℄. De Novo Sequening
assembly is a hallenge and, urrently there is not a single algorithm or soft-
ware that perform this tasks. The assembly results are linked to the overage
of the sequening, the lenght of reads and, the genomi struture of the an-
alyzed organism.[43℄. Among the software used for assembly the most know
are: Newbler[4℄, ABYSS[30℄, CLC[5℄, SOAPdenovo[23℄, and Velvet[35℄.
Generally, for a De Novo sequening it is requested a overage from 30X
to 50X overage. Currently these overages an be obtained with low osts
thanks to NGSs. The most used sequeners for this aim are 454 and ILLU-
MINA.
2.3 Resequening
Resequening is very similar to DeNovo Sequening but, the genome of
the analyzed organism is known. The sope of a resequening is to nd
variations that an be linked to partiular phenotypes. Resequening an
be done over all genome or only in seleted regions (amplions, targeted
resequening and exomes)[44℄. In all ases the overage is the key of the
experiments; mutation disovery generally needs a 20X overage, but studies
in amplions for tumor haraterization need very high overage suh us
1000X or 5000X.
In a resequening projet, the rst operation to do is to map the reads against
the referene admitting mismathes and gaps. Currently there are lots of
software to map the reads and the most used are: PASS[18℄, BOWTIE[41℄,
Newbler[4℄, Soap[23℄, BWA[38℄ and CLC[5℄.
Output of these programs is an alignment, and the standard output is the
SAM/BAM format[6℄.
These output le are input for SNP alling softwares. Chapter 4 and hapter
5 are a deepening of alignments and SNP allers.
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2.4 RNA-Seq and DeNovo transriptomi sequen-
ing
RNA-Seq is a reently developed approah to transriptome proling that
uses NGS tehnologies. Studies using this method have already altered the
view of the extent and omplexity of eukaryoti transriptomes[47℄. RNA-
Seq is generally performed by Illumina or SOLiD and it is requested a refer-
ene (genome or transriptome) where aligning the reads against.
One reads have been obtained, the rst task of data analysis is to map the
short reads from RNA-Seq to the referene genome the same software viewed
in Resequening Chapter. The alignment is very important and not trivial,
outputs need to be then analyzed with dediated statistial tools. The major
problems of the RNA-Seq alignment are:
• reads that math multiple loations.
• gap openings for splied alignments.
Despite the problems desribed above, the advantages of RNA-Seq have en-
abled to generate an unpreedented global view of the transriptome and its
organization.
454 is generally not used for RNA-Seq but, it is prefered for De Novo tran-
sript assembly. Thanks to the long reads of 454 it is possible to identify
transritps of non model speies. The best software to assembly transrip-
tome is Newbler[4℄.
Often, for novel organism where the genome sequene is not known, 454 and
RNA-Seq are ombined to obtain the transriptional prole and the tran-
sriptional dierees in dierent ondition or tissue of the new organism.
2.5 Metagenomis
The term Metagenomis is very ambiguous beause lots of dierents ex-
periment an be lassied like metagenomis. All ases Metagenomis is tool
for studying the diversity and metaboli potential of environmental mirobes,
whose bulk is as yet non-ultivable[32℄. In this senario we an perform sev-
eral dierent experiments foused on the haraterisation of bateria or fungi
in a sample, and all them metagenomis.
One of the most used tehnique for haraterizing the baterial diversity of a
sample is the 16S (for fungi ITS) amplion analysis. In this ase, it is used a
set of primers for amplifying the variable 16S region. There are several tools
to ompute this data: CLOTU[7℄, MOTHUR[8℄ and QIIME[9℄.
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3.1 Introdution
Exome resequening is a speial appliation of the targeted resequening
and has beome a powerful new approah for identifying genes that underlie
Mendelian disorders[16℄[26℄. The exome an be dened as the sum of all
oding sequening regions (CDS).
3.2 Why sequening the human exome?
Despite human exome is only a small part of the entire genome, it on-
tains all the information of the genes and several diseases are related to
variations on genes[15℄.
We an onsider three points to give an answer to the question "Why se-
quening the human exome":
• Positional loning studies foused on protein-oding sequenes have
proved to be highly suessful at identifying variants for monogeni
diseases[45℄.
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Figure 3.1: Exome Capturing methods: A - Solid-phase. B - Liquid-
phase.[20℄
• Many Mendelian disorders are aused by disruption of protein-oding
sequenes[31℄.
• A large fration of variant suh as missense or nonsense single-base
substitutions or small insertiondeletions (indels) in gene oding se-
quene are predited to have funtional onsequenes and/or to be
deleterious[22℄.
3.3 Capture Methods
There are 2 prinipal methods for apturing the exome: Solid-phase hi-
bridization and Liquid-phase hibridization[20℄.
Solid-phase hibridization utilize probes omplementary to sequenes of inter-
est xed to a solid support (miroarray or lters). The non-targeted regions
are washed out and the regions of interest remains on the support.
Liquid-phase hibridization, at ontrary, uses biotinylated probes and the re-
gions of interest are then reovered with magneti streptavidin beads. Figure
3.1 shows the two prinipal methods for apturing the exome. Currently the
most used method is the Liquid-phase hibridization.
Commerial kits now target, at a minimum, all of the RefSeq olletion
and an inreasingly large number of hypothetial proteins. Nevertheless, all
existing targets have limitations. First, the knowledge of all truly protein-
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Figure 3.2: Exome Capturing workow[15℄
oding exons in the genome is still inomplete, so urrent apture probes an
only target exons that have been identied so far. Seond, the eieny of
apture probes varies onsiderably, and some sequenes fail to be targeted by
apture probe design altogether[15℄. In this thesis I take into onsideration
only two ommerial kits: the SOLiD and the Illumina kits.
The workow for the exome enrihment is showed on gure 3.2.
3.3.1 Illumina exome enrihment kit
Illumina exome enrihment kit is alled TruSeq Exome Enrihment Kit.
It is based on hybrid seletion(Fig.3.1),and allows to selet 201071 dierent
regions for a total of 62 Mbp and 20846 genes. The probes apture also
Untraslated Regions (UTRs).
3.3.2 SOLiD exome enrihment kit
SOLiD exome enrihment kit is alled New Target Enrihment Kit. It is
based on hybrid seletion (Fig.3.1), the kit allows to selet 195282 dierent
regions. This kit overs 37 Mbp and 19911 genes.
3.3.3 Comparison of exome enrihment kits
The SOLiD and the ILLUMINA kit are dierent beause of they over
in many ases dierent regions. More preisely:
• Overlapping regions are 186048 bp.
• 33 Mbp are in ommon
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Sample % Reads on target % Reads on target +500 Platform
I2 55,7% 72,1% ILLUMINA
I4 56,6% 74,3% ILLUMINA
I5 53,6% 69.4% ILLUMINA
I6 48,4% 61,8% ILLUMINA
I7 48,6% 62,6% ILLUMINA
I12 55,2% 73,1% ILLUMINA
Table 3.1: Perentage of reads on target in the six patients we analysed
exome with Illumina tehnology.
• ILLUMINA has 29 Mbp exlusive and SOLiD 4Mbp
• The extra regions of ILLUMINA kit are generally UTRs
These dierenes show also that the denition of exome is not globally a-
epted.
Another important thing to take into onsideration is that these kits apture
not only the targeted regions but, often we an nd mithoondrial DNA and
regions anking the target:
• Mithoondrial DNA (we found over all samples with high overage) is
very usefull to hek the sample before and after sequening to avoid
errors (sample exhange). In fat we an sequene the hypervariable
regions (HVR1 and HVR2) before the enrihment and then heking
them after the sequening with NGS. If they are equal we an be sure
that there is no sample exhange.
• Flanking regions are also very important. Several mutations an be on
these region and they an have damaging eets.
In the table 3.1 are reported the perentage of reads aligned against the
target regions and against the target regions plus 500 bp (at 3' and 5') of
the six patients we analysed the exome with ILLUMINA tehnology.
3.4 Appliation of Exome sequening
Human Exome sequening has several appliation both in diagnosti and
in reseah elds. We an nd 3 prinipal appliations [20℄:
• Medial eld
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• Human Evolution
• Biologial eld
3.4.1 Medial Field
In the medial eld, human exome sequening nds a lot of applia-
tions. Several disease are assoiated with DNA variations in exomi re-
gions (mendelian diseases or other well haraterized diseases)and exome
resequening an be used for diagnosti purpuses. For example Ng et al[25℄
sequened 12 human exome from patients with Freeman-Sheldon disease that
is a rare syndrome lassied like dominantly inherited rare Mendelian disor-
der. In the study, researhers were able to nd the variations ausative of
the disease.
Many other studies was performed for mendelian diseases (autosomal re-
essive ataxia[19℄, papillorenal syndrome[29℄) and, in several ases human
exome resequening allowed to nd the ausative mutations.
These studies demostrated that exome resequening an be used for diag-
nostis purpuses and in this thesis I investigated about the appliation of
exome resequening for the diagnosis of arrhythmogeni ardiomyopathy.
At the same time it is very important to onsider that having the exome
means also to have lots of data that an be useful for future studies. In
fat whith exome resequening we have a photo of all the variations of an
individual that an be useful for researh purpuses. For example if we are in-
vestigating about an unknown disease we an analyse all the anditated mu-
tations ltered with ommon mutations from unrelated patients sequened
for other reasons.
3.4.2 Human Evolution
Like speied in the last subsetion, having the exome of an individual
means to have a photo of all variants of this individual. These allow to
perform omparisons beetween dierent persons from dierent populations
and extrat andidates mutations that an explain the dierent phenotypes.
A similar study has been performed by Yi et al[34℄, where it was ompared
exomes from high-altitude and low-altitude populations to identify possible
dierenes in allele frequenies that an explain dierent adaptations.
In this study, there were found a disrete number of genes possible andidated
for the high altitude adaptation.
3.4.3 Biologial Field
Copy number variations (CNVs) and genomi strutural variations are
large variations that have been onsidered in the last few years. CNVs are
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insertions, deletions or dupliations of genes or other regions of the genome
while, genomi strutural variations are generally inversions or transloations
of piees of genome.
Both variations are in some ases linked to diseases and they an be deteted
also by exome sequening[21℄[42℄.
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4.1 Introdution
The rst step after the sequening of an exome is the alignment. We are
onsidering the human exome so the alignment have to be performed against
the human genome. There are several software to align short reads against
a referene but in every ase we have to align admitting mismathes and
indels. Even if it may be seem a simple task, align short reads is not trivial,
there are several software available based on dierent algorithms.
Mapping results inuene the results of SNP Calling software, so it is very
important to hoose a good aligner with the best parameters.
Mapping the reads against a referene means nding the position of the
sequened piee of genome on the referene taking into onsiderations se-
quening errors and variations.
There are two major problems when we onsider the mapping and the NGS
output: the rst problem is the amount of data and the time neessary to
align; the seond one is the reads that seem to have multiple solutions[17℄.
Both problems are very important and they an be onneted.
Align billions of reads an be very time onsuming and urrently algorithms
tried to be as faster as possible. The problem of multiple mapping reads is
onneted to the read length and it is important to onsider 2 properties of
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a mapped reads:
• The best hit.
• The unique hit.
The best hit is the best position of the reads onto the genome indipendently
by the number of mismathes or indels. Generally, every alignment has a
sore and the best hit is the alignment with the best sore. Sometimes, a
read an have multiple best hit, so we an map this read in dierent position
and we don't known what is the real position of this read onto the genome.
When a reads has only one best hist, it is alled unique best hit. Read lenght
is strily orrelated to the unique best hit, short reads tend to have several
best hit only for statistial questions.
To understand the relation between read lenght and unique hit, we have to
onsider that a read with length N has N
4
possible ombinations (we have
4 nuleotides).
If N is equal to 10, the possible ombinations are 10000, so the probability of
nd our string is 1/10000. The human genome is 3Gbp and we an alulate
the number of 10 length strings: it is 3000000000 - 10 + 1, so we expet at
least 300000 strings equal to our one. (We onsider the human genome like
a random string omposed by 4 letters).
If N inrease, the probabilty of nd the same string derease. This is true if
the human genome is a random string, but this not the ase of genomes. In
addition, genomes have repetitive regions of dierent lengths that inrease
the probability to nd multiple hits for short reads.
The dierent algorithms used for mapping short reads an hoose 3 dierent
solutions for multiple hit:
• Ignore the multiple hits.
• Consider only a part of all the hits.
• Consider all the hits.
The last solution an inrease markedly the proessing time for mapping.
4.2 Mapping strategies
Several algorithms had been developped to map reads against a referene;
the goal is always nd the real position of the reads onto the referene limiting
proessing time and hardware equipments. In all ases the prinipal problems
are the reads lengths and the number of reads to align.
The most used software are bases on indexing strategies: some software
prefers to index the reads, other ones prefer to index the referene. Indexing
an take several time and an reate large les used then for the alignments.
In this thesis I take into onsideration 5 dierent software:
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• Pass.
• Bowtie.
• Bfast.
• CLC.
I don't talk about the alignment algorithms, but, I onsider only the prinipal
haraterystis of the mapping software.
4.2.1 PASS
Pass[18℄ is a mapping software developped at CRIBI (University of Padua).
PASS an align short reads in bases spae (Illumina) and in olor spae
(SOLiD), and it uses a very fast algorithm based on genome indexing. PASS
uses short words for plaing the reads on the genome and then renes the
alignment using a sort of Smith-Watermann algorithm. In my projet PASS
was used to align SOLiD data.
4.2.2 BOWTIE
Bowtie[41℄ is based on Burrow-Wheeler transform. Bowtie is very fast
but it takes several time to onstrut the indexes (on the genomes). Another
advantage of BOWTIE is the hardware request: BOWTIE an align against
the human genome using a laptop, it requires few Giga of RAM. In the thesis
BOWTIE had been used to align ILLUMINA reads.
4.2.3 BWA
BWA (Burrows-Wheeler Aligner)[37℄[36℄ is an eient program that aligns
short sequenes against a long referene sequene suh as the human genome.
It implements two algorithms, bwa-short and bwa-sw. The former works for
query sequenes shorter than 200bp and the latter for longer sequenes up
to around 100kbp. Both algorithms do gapped alignment. BWA needs to
index the referene and this operation an take several time. Like BOWTIE
it is based on Burrow-Wheeler transform.
4.2.4 CLC
CLC[10℄ is a ommerial suite that oer several tools for genomis and
transriptomis analyses.
CLC mapper is based on a seeding approah. The algorithm iterates over
input reads and maps eah read individually by applying the following pro-
edure: seeding sequenes of 30 nuleotides eah are sampled from eah third
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position of the input read. These seeds are looked up in the index and re-
sulting andidate alignment loations are examined using a banded Smith
Waterman.
4.3 Mapper Evaluation
It is very diult to evaluate the results of a mapper beause we an take
into onsideration dierent parameters. The best way should be to have a
set of reads with known position and with known mismathes.
In my PHD thesis, I take into onsideration real data so it is not known the
real position of eah read. So, the evaluations has been made taking into
onsideration the number of aligned reads. Results are report in the hapter
6. For all software I used default parameters.
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5.1 Introdution
SNP Callers are a series of tools that extrat variants from an alignment.
The problems, in SNP Callers, are the high error rate of the base alling and
the errors in alignments. Under suh irumstanes, aurate SNP alling
are diult and there is often onsiderable unertainty assoiated with the
result[28℄.
The problem of error rate assoiated to the NGSs an be by-passed with
high overage; the alignment problems otherwise an be solved only using a
good mapper.
In this PHD thesis I take into onsideration 2 SNP Caller: CLC Variant
Probabilisti aller and GATK[24℄.
5.1.1 GATK:Genome Analysis ToolKit
GATK is a suite designed to enable rapid development of eient and
robust analysis tools for next-generation DNA sequeners. This is the most
used tools and one of the most itated.
GATK inludes a series of analysis for variant alling and it aepts a BAM
le in input.
There are several workow for GATK; in this thesis I used the workow
desribed in gure 5.1.
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Figure 5.1: GATK Workow
Realigner Target Creator and Realignment
With this tool, GATK suite performs a realignment of some intervals
using Smith-Watermann algorithm[46℄. To speed up this operation, GATK
in a rst phase nd the andidate regions analysing the BAM le; then only
these regions are realigned using Smith-Waterman.
The idea is to minimize the number of mismathes espeially in those regions
where there are indels. In general, a large perent of regions requiring loal
realignment are due to the presene of an insertion or deletion in the individ-
ual's genome with respet to the referene genome. Suh alignment artifats
result in many bases mismathing the referene near the misalignment, whih
are easily mistaken as SNPs.
Quality Realibration
In this phase, GATK performs a orretion of the quality sore of the
reads in the BAM le. To realibrate the quality sore, GATK analyse three
parameters:
• The reported quality sore.
• The position of the nuleotide in the reads.
• The preeding and urrent nuleotide.
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Using these 3 parameters, GATK is able to orret the quality sore of the
bases.
SNP Calling
After BAM orretion, GATK an perform the SNP alling. GATK is de-
signed also for multiple samples using a Bayesian genotype likelihood model
to estimate simultaneously the most likely genotypes and allele frequeny in
a population of N samples.
SNP alling is performed observing mismathes and indels in the alignment
le and taking into onsideration the overage, the frequeny of the varia-
tions and the strand of the aligned reads.
At the same time GATK gives a sore for eah variant alled (Variant Real-
ibration and Variant Filtration). Eah variant has also a sort of omment to
better indentifying problemati result (suh as low overage or strand bias
that an reate artifats).
5.1.2 CLC Probabilisti Variant Caller
CLC Probabilisti Variant Caller[11℄ is a tool of the ommerial CLC
suite. Probabilisti Variant Caller has been designed for alling variants
in haploid (bateria), diploid (human) and polyploid genomes (aner or
plants). The tool is very simple to use and it take as input a CLC align-
ments le. The alignment an be performed using CLC or using also other
mapper, the result BAM le an be uploaded in CLC Workspae.
The CLC Variant Caller algorithm ombines a Maximum Likelyhood ap-
proah with a Bayesian model to all the variants and to give to eah one a
sore that represent the probability of the variant.
More preisely it is rst alulated a prior probability using only the
alignment. The starting parameters are shown in gure 5.2.
These parameters are updated using an Expeted Maximization approah.
At the same time it is alulated an error probability taking into onsider-
ation also the quality sore of the aligned reads, and for eah quality sore
it is alulated a dierent error probability table.
After the prior and the error probability have been estimated the Variant
Caller give in output the most probable allele for eah position.
CLC output is a table of variants with several parameters like overage,
forward/reverse reads and probability of the variant.
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Figure 5.2: Initial probability of CLC Variant Caller
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6.1 Introdution
Arrhythmogeni right ventriular ardiomyopathy (ARVC) is an inher-
ited myoardial disease assoiated with signiant genotype and phenotype
heterogeneity. The strutural features of ARVC onsist of progressive bro-
fatty replaement of myoytes and, linially, the disease has been assoiated
with ventriular arrhythmias at risk of sudden ardia death[27℄.
In my thesys I take into onsideration 6 patients with ARCV disease already
haraterized with Sanger. The exome of the 6 patientshas been enrihed
and sequened using Illumina and SOLiD strategy.
6.2 Results
6.2.1 Mapping Results
After sequening, reads were aligned against the human genome using
CLC, PASS, BOWTIE and BWA using default parameters. BOWTIE and
BWA required a preliminary indexing of the referene that take several hours.
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Sample Number of reads Tehnology
2 17.250.274 ILLUMINA
6S 49.719.032 SOLID
4 81.382.994 ILLUMINA
5 70.603.922 ILLUMINA
6 48.166.720 ILLUMINA
7 52.233.528 ILLUMINA
12 33.786.456 ILLUMINA
Table 6.1: Number of reads sequened per sample.
Sample # of Reads PASS CLC BOWTIE BWA
2 17.250.274 75,97% 87,18% 81,81% 86,89%
6S 49.719.032 67,18% 75,61% - -
6 48.166.720 80,64% 86,75% 62,19% 76,90%
12 33.786.456 83,88% 86,75% 86,01% 93,91%
Table 6.2: % of reads aligned with PASS, CLC, BOWTIE and BWA.
CLC and PASS did not required this indexing.
The fastest software was CLC followed by BWA, BOWTIE and PASS. For
all the software I take into onsideration the number of unique aligned reads
admitting 2 mismathes and gaps. For SOLiD reads I used only PASS, CLC
and BFAST [12℄[40℄[39℄ (BFASTA uses an algorythm vary similar to PASS).
The sequening of six patients produed dierent number of reads and for the
software evaluation I onsidered only the 3 patients with the lowest number
of reads. This hoise has been made for minimize the proessing time for the
alignments. In the table 6.1 there is reported the number of reads produed
by the sequeners.
The samples hosen for the mapper evaluation was the samples 12, 2 and 6
for Illumina and the sample 6S for SOLiD. In the table 6.2 are reported the
results obtained with the 4 mappers.
Table 6.2 shows that the mapper with the higher number of unique best hit
is CLC; so, we hoose CLC like prinipal software for the alignments. CLC
is also the simpliest software to use thanks to its graphial interfae.
In table 6.3, there are showed the results of the alignments of all samples
and the average overage of the exome. Like speied in Chapter 3, Illumina
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Sample # of Reads % aligned (unique) Avg Exome Coverage
2 17.250.274 87,18% 9,24X
6S 49.719.032 75,61% 40,01X
4 81.382.994 84,79% 51,65X
5 70.603.922 85,32% 41,53X
6 48.166.720 86,75% 25,07X
7 52.233.528 85,91% 27,36X
12 33.786.456 86,75% 20,04X
Table 6.3: % of reads aligned with CLC over all samples.
Sample Tehnology % reads on target % referene not overed % referene over 20X
4 ILLUMINA 56,6% 3,96% 81,03%
5 ILLUMINA 53,6% 3,73% 75,08%
7 ILLUMINA 48,62% 4,84% 53,52%
6 ILLUMINA 48,24% 5,76% 48,35%
12 ILLUMINA 55,21% 7,83% 38,65%
2 ILLUMINA 55,76% 22,14% 11,07%
6S SOLiD 70,11% 9,56% 60,27%
Table 6.4: Table with overage data of 6 patients. Reads has been aligned
with CLC.
and SOLiD have dierent kits. The average overage is alulated like:
total_nucleotide_aligned_on_the_exome
total_nucleotide_of_the_exome
Exome sequening is a targeted resequening, and beyond the average over-
age there are other parameters that have to be onsidered for understanding
the dierenes in the sample. These parameters are reported in table 6.4.
Reads on target are all the reads that maps on the exome. With illumina
kit, we have the 50% of reads that maps on the target while, with SOLiD
kit we had the 70%. If we onsider the targeted regions plus 500 bp in 5'
and in 3', the perentage of reads on target inrease of 20%. These onrm
that also these regions are overed and we an onsider also the variations
alulated for these extra-regions. Like expeted the other data in table 6.4
(% referene not overed and % of referene over 20X ) are strily related
to the average overage of the samples. I reported also the perentage of
referene over 20X overage beause, like explained later, at this overage
we have the best result for variation alling.
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Sample Gene Chr Position Sanger GATK CLC CASAVA
4 DSG2 18 29104698 C/T C/T C/T C/T
4 DSG2 18 29125854 A/G A/G A/G A/G
4 DSG2 18 29126670 T/C Not found T/C Not found
4 DSP 6 7542149 -/A Not found -/A Not found
4 DSP 6 7563983 G G G G
4 DSP 6 7572262 G G G G
4 DSP 6 7572026 A/T A/T A/T Not found
4 DSP 6 7576527 A A A A
4 DSP 6 7584617 C/T C/T C/T C/T
4 DSP 6 7585967 A A A A
5 PKP2 12 32948970 GT/A Not found A Not found
5 PKP2 12 32945721 C/A C/A C/A Not found
5 PKP2 12 32945769 C/G C/G C/G Not found
5 DSG2 18 28666526 +TAA +TTAA +TAA Not found
5 DSP 6 7567970 T T T Not found
5 DSP 6 7572026 A A A Not found
5 DSP 6 7559633 A A A Not found
5 JUP 17 39914070 A/C A/C A/C Not found
5 JUP 17 39913645 A/G A/G A/G Not found
Table 6.5: Table with Variant of Samples 4 and 5. There is reported the
Sanger result and the output of CLC, GATK and CASAVA.
6.2.2 SNP Caller Results - Illumina Data
After alignments we performed the SNP Calling. SNP Callers take as
input BAM les that are the binary format of SAM, the standard alignment
output. We onsidered GATK and CLC Variant Probabilisti aller.
GATK required lots of step to produe the output and the pipeline took also
lots of time (more or less one day per sample).
To evaluate the variant allers I foused my attention on the best samples,
the samples 4 and 5 that are the ones with the highest overage for Illumina
sequening. For SOLiD sequene I used the sample 6S that was the unique
avaliable.
Sample 4 and 5 was analyzed using GATK, CLC and CASAVA. CASAVA is
the standard suite for Illumina data analyses and performs alignment (with
ELAND) and SNP/DIP Calling. Software evaluation was performed on-
sidering a series of known variant previously haraterized using SANGER
Tehnology. For eah variant we heked the SANGER sequene quality and
we heked the presene in the variant aller outputs.
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Sample Gene Chr Position Exome position Coverage
4 DSG2 18 29104698 IN 64
4 DSG2 18 29125854 IN 92
4 DSG2 18 29126670 IN 62
4 DSP 6 7542149 IN 9
4 DSP 6 7563983 IN 67
4 DSP 6 7572262 IN 39
4 DSP 6 7572026 OUT 32
4 DSP 6 7576527 IN 36
4 DSP 6 7584617 IN 74
4 DSP 6 7585967 IN 37
5 PKP2 12 32948970 OUT 8
5 PKP2 12 32945721 OUT 17
5 PKP2 12 32945769 OUT 10
5 DSG2 18 28666526 OUT 18
5 DSP 6 7567970 OUT 14
5 DSP 6 7572026 OUT 14
5 DSP 6 7559633 IN 5
5 JUP 17 39914070 OUT 12
5 JUP 17 39913645 OUT 30
Table 6.6: Positions of variants respet the enrihed regions
Table 6.5 shows the results. In this table CASAVA seems to be the worst
software but we have to onsider that CASAVA extrats variants limited to
the enrihed regions. Lot of the position reported for samples 4 and 5 are
out of the enrihed regions (see table 6.6). CASAVA was disarded for its
inability to nd variants out of enrihed regions.
At ontrary, GATK and CLC are able to detet variants in all overed re-
gions even if these regions are out of the exome.The performanes of GATK
and CLC are very similar but observing the table 6.5 we an see that GATK
had some diulties in detet indels (indel -/A in position 7542149 hromo-
some 6 for the sample 4 and indel -/TAA in position 28666526 hromosome
18 for the sample 5). The unique problem with CLC is the variant in posi-
tion 32948970 hromosome 12 in the sample 5: here CLC alled a variant in
omozygosis but SANGER sequenes found the same variant in eterozygosis.
For better understanding this results I take into onsideration also the ov-
erage. Like reported in table 6.6 this variation has a low overage (8X).
These results suggested that the most reliable software is CLC Variant Prob-
abilisti Detetor and I analyzed all the other samples with CLC. In the table
6.7 are reported the results.
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Sample Average Coverage # of variant from Sanger # of variant orret from CLC
4 51,65X 10 10
5 41,53X 10 9
6 25,07X 9 7
7 27,36X 10 10
2 9,24X 12 5
12 20,04X 9 6
Table 6.7: Number of variants found by Sanger ompared with the CLC
output
Figure 6.1: % of orret outputs of CLC divided by overage
Analysing these data, it is lear that there is a strily relationship among the
overage and the performane of the SNP aller, but the average overage
an be only an approximate parameter. More interesting is the relation
among the result of CLC and the overage of every variant. In the gure 6.1
I onsidered all the variants indipendently from the sample; I divided the
overage in 5 lass and I onsidered the orreted predition of CLC against
the total of variants. Observing the gure 6.1, it appears that the minimum
overage for having reliable results is 20X. The total results divided per
sample are reported in the supplementary materials.
6.2.3 SNP Caller Results - SOLiD Data
For the SOLiD data, we had only one sample (6S) and it is very diult
to extrat some statistis having only one sample. For SOLiD data I take
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Position Chr SANGER CLC PASS/GATK BFAST/GATK
32974422 12 G/- G/- NotFound NotFound
7558318 6 T/C T/C T/C T/C
7578819 6 G G/A G G
7578823 6 A A/G A A
7584617 6 C/T C/T C/T C/T
7585967 6 C NotFound NotFound C
28673760 18 No Coverage No Coverage No Coverage No Coverage
28672067 18 T/C T/C T/C T/C
Table 6.8: Results of SOLiD Data
Algorithm Total variants found Variants annotated with dbSNP
CLC 115.681 52.283
BFAST/GATK 48.097 42.213
PASS/GATK 79.478 51.970
Table 6.9: Results of Variant Caller on SOLiD Data
into onsideration CLC and GATK.
CLC was used starting from CLC mapping, while GATK was used starting
from aligments obtained with PASS and BFAST[12℄[40℄[39℄.
Results are reported in table 6.8. Unlike with Illumina Data, CLC does
not perfom very well, probably olor spae is more omplex to align and
speialized software like PASS and BFAST perform better.
It is important to onsider that 50% of known variants are out of the enrihed
regions and one has no overage. The total number of variants alled by the
three elaborations of sample 6S are reported in table 6.9.
The three algoritms found 34.305 ommon variants.
These data are very diult to interpretate. Theoretially within the same
sample we should obtain same data. Probably olor spae is very diult to
trait and the result an vary.
6.2.4 SNP Analyses
The table 6.10 reports the total number of variants alled by CLC and
the variants that are known aording to DBSNP[13℄. I onsidered only the
samples sequened with Illumina.
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Sample Total Number of Variants Variants with DBSNP ode
2 99.600 54.648
4 286.124 165.948
5 320.178 159.853
6 254.541 124.628
7 276.340 134.968
12 195.672 110.996
Table 6.10: Total number of Variant per sample and total number of known
variants aording to DBSNP
The 50% of alled variants are known with a DBSNP ode and the number
of variant is strily orrelated to the overage: samples with higher overage
have more variants alled; probably the number of false positive inrease
with the overage. The six samples share 30.028 variants and 18.374 are
known in DBSNP.
Sample 6 and 6S are the same sample sequened with Illumina(6) and SOLiD(6S).
Comparing the variants alled with CLC we see that they shared 47.957
variants (Sample 6S has 115.681 variants alled using CLC variant aller).
Pratially all variants found by BFAST and GATK are in ommon with the
PASS/GATK and the CLC ones.
6.2.5 Disussion
Currently, exome sequening is one of the most hallenge approah used
to haraterize human disease. Results depends on two fator: the mapping
and the snp alling algorithms. Moreover results of mapping inuene the
snp alling results. We saw that hanging alignment algorithm, hange also
the output of snp aller. The most diult task is to understand the real
position of a read on the referene taking into onsideration sequening er-
rors and real dierenes. On the other hand, SNP aller must to be able
to onsider dierent level of overage and dierenes in the quality of reads
to right assign a variation in a partiular oordinate of the referene. At
the moment there is not a standard approah to alulate the variants of an
exome sequening, but, in this thesis I observed that CLC suite perform bet-
ter than the other pipelines using illumina data. With SOLiD data CLC do
not perform very well, GATK, using PASS or BFAST alignments, perfomed
better.
GATK had problems in deletion/insertion reognization.
CLC performs very well when the overage is >20X. Observing the table
6.4 we an say that the minumun average overage for having a reliable snp
alling result is at least 70X. At this average overage we have at least the
80/90% of the exome overed with at least 20 indipendent reads and the
results are very robust.
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Additionally, CLC is very simple to use and it an be used also by biologists
that do not have bioinformatis ompetenes. It is very fast and an be run
on laptop omputer.
Using the Sanger sequenes I tried also to alulate false positive and false
negative. I analysed 7.989 nuleotides and I found only 2 false negative re-
sults. Observing the overage I saw that the 2 false negative results is under
the 20X overage (the rst is 8X, and the seond is 1X), and the rest of
nuleotides has very high overage. These data onm the key role of the
overage in the snp alling results. In the 7.989 nuleotides analized I don't
nd any false positive results. These don't means that there aren't false
positive, I belive that false posivite are present and that these false positive
are strily orrelated to the overage.
Filtering the data by overage, the number of variants derease drastially
(see table 7.7 in supplementary data); probably also the number of false
positive derease.
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Chapter 7
Supplementary Material
Sample Position Chr SANGER CLC Coverage
4 29104698 18 C/T C/T 64
4 29125854 18 A/G A/G 92
4 29126670 18 C/T C/T 62
4 7542149 6 -/A -/A 9
4 7563983 6 G G 67
4 7572262 6 G G 39
4 7572026 6 T/A T/A 32
4 7576527 6 A A 36
4 7584617 6 C/T C/T 74
4 7585967 6 C C 37
Table 7.1: Illumina Sample 4 Results
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Sample Position Chr SANGER CLC Coverage
5 32948970  71 12 T/AC AC 8
5 32945721 12 C/A C/A 17
5 32945769 12 G/C G/C 10
5 28666526 18 -/TAA -/TAA 15
5 7567970 6 T T 14
5 7572026 6 A A 14
5 7559633 6 A A 5
5 39914070 17 G/T G/T 12
5 39913645 17 T/C T/C 30
Table 7.2: Illumina Sample 5 Results
Sample Position Chr SANGER CLC Coverage
6 32974422 12 G/- G/- 18
6 7558318 6 T/C NotFound 11
6 7578819 6 G G 10
6 7578823 6 A A 10
6 7584617 6 C/T C/T 28
6 7585967 6 C C 10
6 28673760 18 G/A NotFound 1
6 28672067 18 T/C T/C 12
Table 7.3: Illumina Sample 6 Results
Sample Position Chr SANGER CLC Coverage
7 7567970 6 C/T C/T 8
7 7572262 6 A/G A/G 20
7 7572026 6 T/A T/A 11
7 7578189 6 G/A G/A 28
7 7578816 6 G G 15
7 7578823 6 A A 12
7 29104714 18 A/G A/G 37
7 39913645 17 T/C T/C 11
7 39912145 17 A/T A/T 10
7 39911771 17 G/A G/A 34
7 7585967 6 C C 20
Table 7.4: Illumina Sample 7 Results
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Sample Position Chr SANGER CLC Coverage
2 7542149 6 A/+A No Coverage 0
2 7563983 6 G G 5
2 7565227 6 A/T No Coverage 0
2 7576527 6 G/A NotFound 7
2 7584617 6 T/C T/C 7
2 28649057 18 G NotFound 2
2 32994007 12 G/- NotFound 3
2 32977104 12 -/A -/A 5
2 29104553 18 T/C T/C 10
2 29104569 18 A/G A/G 11
Table 7.5: Illumina Sample 2 Results
Sample Position Chr SANGER CLC Coverage
12 33030802 12 A/G NotFound 4
12 30049475 12 G/A No Coverage 0
12 32949029 12 G G 11
12 33021819 12 C NotFound 2
12 28669496 18 C C 8
12 7563983 6 G G 25
12 7572262 6 G G 15
12 7576527 6 A A 13
12 7584617 6 C/T C/T 31
Table 7.6: Illumina Sample 12 Results
Sample Number of variants with overage > 20X Total Number of variants
2 22.009 99.600
4 140.088 289.124
5 127.290 320.178
6 78.117 254.541
7 84.979 276.340
12 57.555 195.672
Table 7.7: Variants with a overage higher than 20X
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